-
Type
Peer-Reviewed Article -
Tags
Industrial -
Strategic pillar
All -
Beamlines
CMCF -
From Year
2007 -
To Year
2024 -
Quarter
2017 - Q1- All
- 2024 - Q4
- 2024 - Q3
- 2024 - Q2
- 2024 - Q1
- 2023 - Q4
- 2023 - Q3
- 2023 - Q2
- 2023 - Q1
- 2022 - Q4
- 2022 - Q3
- 2022 - Q2
- 2022 - Q1
- 2021 - Q4
- 2021 - Q3
- 2021 - Q2
- 2021 - Q1
- 2020 - Q4
- 2020 - Q3
- 2020 - Q2
- 2020 - Q1
- 2019 - Q4
- 2019 - Q3
- 2019 - Q2
- 2019 - Q1
- 2018 - Q4
- 2018 - Q3
- 2018 - Q2
- 2018 - Q1
- 2017 - Q4
- 2017 - Q3
- 2017 - Q2
- 2017 - Q1
- 2016 - Q4
- 2016 - Q3
- 2016 - Q2
- 2016 - Q1
- 2015 - Q4
- 2015 - Q3
- 2015 - Q2
- 2015 - Q1
- 2014 - Q4
- 2014 - Q3
- 2014 - Q2
- 2014 - Q1
- 2013 - Q4
- 2013 - Q3
- 2013 - Q2
- 2013 - Q1
- 2012 - Q4
- 2012 - Q3
- 2012 - Q2
- 2012 - Q1
- 2011 - Q4
- 2011 - Q3
- 2011 - Q2
- 2011 - Q1
- 2010 - Q4
- 2010 - Q3
- 2010 - Q2
- 2010 - Q1
- 2009 - Q4
- 2009 - Q3
- 2009 - Q2
- 2009 - Q1
- 2008 - Q4
- 2008 - Q3
- 2008 - Q2
- 2008 - Q1
- 2007 - Q4
- 2007 - Q3
- 2007 - Q2
- 2007 - Q1
- 2006 - Q4
- 2006 - Q3
- 2006 - Q2
- 2006 - Q1
- 2005 - Q4
- 2005 - Q3
- 2005 - Q2
- 2005 - Q1
- 2004 - Q4
- 2004 - Q3
- 2004 - Q2
- 2004 - Q1
- 2003 - Q4
- 2003 - Q3
- 2003 - Q2
- 2003 - Q1
Publication | Beamlines | Type | Strategic Pillar |
---|---|---|---|
Duclos, Franck; Abell, Lynn M.; Harden, David G.; Pike, Kristen; Nowak, Kimberly et al. (2017). Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. MedChemComm 8(11) , 2093-2099. 10.1039/c7md00268h. [PDB: 5wdj] | CMCF-ID | Peer-Reviewed Article | Health |
Stanger, Frédéric V.; de Beer, Tjaart A.P.; Dranow, David M.; Schirmer, Tilman; Phan, Isabelle et al. (2017). The BID Domain of Type IV Secretion Substrates Forms a Conserved Four-Helix Bundle Topped with a Hook. Structure 25(1) , 203-211. 10.1016/j.str.2016.10.010. [PDB: 4yk1] | CMCF-ID | Peer-Reviewed Article | Health |
Planken, Simon; Behenna, Douglas C.; Nair, Sajiv K.; Johnson, Theodore O.; Nagata, Asako et al. (2017). Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. Journal of Medicinal Chemistry 60(7) , 3002-3019. 10.1021/acs.jmedchem.6b01894. [PDB: 5ugc] | CMCF-ID | Peer-Reviewed Article | Health |
Eastman, Kyle J.; Parcella, Kyle; Yeung, Kap-Sun; Grant-Young, Katharine A.; Zhu, Juliang et al. (2017). The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase. MedChemComm 8(4) , 796-806. 10.1039/c6md00636a. [PDB: 5twn] | CMCF-ID | Peer-Reviewed Article | Health |